Risk-reduction mastectomy: Clinical issues and research needs

Journal of the National Cancer Institute

Volumn 93, Issue 17, 2001, Pages 1297-1306

  Stefanek, Michael ^a,c   Hartmann, Lynn ^b   Nelson, Wendy ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; BREAST EXAMINATION; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL EXAMINATION; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; GENE MUTATION; HETEROZYGOTE; HIGH RISK PATIENT; HUMAN; MAMMOGRAPHY; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL RESEARCH; ONCOGENE; OVARIECTOMY; PATIENT SATISFACTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; SURGICAL RISK;

EID: 0035812281     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.17.1297     Document Type: Review

References (79)

1. Recommendations for medical management of hereditary breast and ovarian cancer: The French National Ad Hoc Committee
2. Bilateral prophylactic mastectomy: Issues and concerns
3. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing
4. A descriptive study of BRACA1 testing and reactions to disclosure of test results
5. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer
6. Breast cancer incidence subsequent to surgical reduction of the female breast
7. Breast cancer following breast reduction surgery in Sweden
8. Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations
9. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: A decision analysis
10. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
11. Breast and ovarian cancer incidence in BRCA1-mutation carriers
12. Subcutaneous mastectomy data: A final statistical analysis of 1500 patients
13. Projecting individualized probabilities of developing breast cancer for white females being examined annually
14. Efficacy of bilateral prophylactic mastectomy in BRCA1/2 mutation carriers
15. Breast cancer after prophylatic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation
16. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines
17. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination
18. Decision-making about breast cancer susceptibility testing: How similar are the attitudes of physicians, nurses practitioners, and at-risk women?
19. The practice of prophylactic mastectomy: A survey of Maryland surgeons
20. How American oncologists treat breast cancer: An assessment of the influence of clinical trials
21. Acceptability of prophylactic mastectomy in cancer-prone women
22. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer
23. Bilateral prophylactic mastectomy decision making: A vignette study
24. Cultural basis for differences between US and French clinical recommendations for women at increased risk of breast and ovarian cancer
25. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations
26. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes
27. Comparison of full-field digital mammography with screen-film mammography for cancer detection: Results of 4,945 paired examinations
28. First experiences in screening women at high risk for breast cancer with MR imaging
29. Earlier detection of breast cancer by surveillance of women at familial risk
30. Reproductive factors and breast cancer
31. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers
32. Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy
33. Efficacy of screening mammography: A meta-analysis
34. Report of the International Workshop on Screening for Breast Cancer
35. The breast-screening brawl
36. An overview of the breast cancer screening controversy
37. National Institutes of Health Development Conference Statement: Breast cancer screening for women ages 40-49, January 21-23, 1997
38. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2
39. Effect of age, breast density, and family history on the sensitivity of first screening mammography
40. Performance of screening mammography among women with and without a first-degree relative with breast cancer
41. The psychosocial consequences of mammography
42. Ten-year risk of false positive screening mammograms and clinical breast examinations
43. Predicting the cumulative risk of false-positive mammographs
44. Outcomes of modern screening mammography
45. Radiation risk from screening mammography of women aged 40-49 years
46. Benefits versus risks from mammography: A critical reassessment
47. Breast cancer screening
48. Breast cancer screening among women in their forties: An overview of the issues
49. Periodic screening for breast cancer: The HIP Randomized Controlled Trial
50. The Edinburgh randomised trial of breast cancer screening: Results after 10 years of follow-up
51. Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years
52. Canadian National Breast Screening Study: 2. Breast cancer detection and death rates among women aged 50 to 59 years
53. Does this patient have breast cancer? The screening clinical breast examination: Should it be done? How?
54. Breast self-examination proficiency and training effects: Women at increased risk of breast cancer
55. Breast self-examination among women at increased risk: Assessment of proficiency
56. Breast cancer screening
57. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
58. Chemoprevention of breast cancer
59. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer
60. Tamoxifen prevention of breast cancer: An instance of the fingerpost
61. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: A case-control study
62. Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women
63. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
64. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: Tamoxifen and raloxifene
65. Predictors of and satisfaction with bilateral prophylactic mastectomy
66. Prevention in familial breast cancer: Counseling and prophylactic mastectomy
67. Patient regrets after bilateral prophylactic mastectomy
68. The psychosocial impact of bilateral prophylactic mastectomy: Prospective study using questionnaires and semistructured interviews
69. Look forward and back: Distress among women at familial risk for breast cancer
70. Trauma history as a predictor of psychologic symptoms in women with breast cancer
71. Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?
72. Decision aids for patients considering options affecting cancer outcomes: Evidence of efficacy and policy implications
73. Prophylactic mastectomy
74. SSO develops position statement on prophylactic mastectomies
75. Proportion of breast cancer cases in the United States explained by well-established risk factors
76. Breast cancer prevention trials